A clinical study from UCLA demonstrated that pembrolizumab, an immunotherapy targeting the PD-1 receptor, induced durable tumor regression in patients with unresectable desmoplastic melanoma, a rare and treatment-resistant skin cancer subtype. The therapy's success offers hope for patients with limited options, highlighting immunotherapy's expanding role in oncology, particularly for aggressive and refractory cancers.